The global dipeptide peptidase 4 inhibitors market size was estimated to be USD 11.47 billion in 2023 and is expected to reach USD 15.81 billion by 2034 with a CAGR of 2.96% during the forecast period 2024-2034. The rising prevalence of type 2 diabetes, enhanced efficacy and tolerability, expanding applications, increased awareness and adoption, rising technological advancements, and government initiatives and support will drive the market growth.
Diabetes, especially type 2, affects millions of people globally and is a serious global health problem. An increasing number of people need efficient diabetes treatment methods due to the condition's rising incidence, which is fueled by factors including obesity, sedentary lifestyles, and aging populations. DPP-4 inhibitors are a popular choice among patients and medical professionals since they provide a secure and efficient means of regulating blood sugar levels. For instance, Boehringer Ingelheim and Eli Lilly will introduce a novel combination medicine containing metformin and linagliptin in September 2023 to enhance glucose management.
By type, the sitagliptin segment accounted for the highest revenue-grossing segment in the global dipeptide peptidase 4 inhibitors market in 2023 owing to the compound's widespread adoption as a first-line treatment for type 2 diabetes, its established efficacy in glycemic control, and its favorable safety profile. For instance, in August 2023, the FDA approved Novartis's Galvus extended-release pills, which provide the convenience of a once-daily dosage. Additionally, the alogliptin segment is predicted to grow at the fastest CAGR during the forecast period owing to the drug's unique pharmacological characteristics, increasing research and development activities, and a growing recognition of its efficacy in glycemic control.
By application, the type 2 diabetes segment accounted for the highest revenue-grossing segment in the global dipeptide peptidase 4 inhibitors market in 2023 owing to the escalating prevalence of type 2 diabetes worldwide, the increasing adoption of DPP-4 inhibitors as a preferred oral treatment option, and the growing emphasis on personalized and effective management strategies for individuals with type 2 diabetes. For instance, in July 2023, AstraZeneca and Merck & Co. will work together on a research project to create next-generation DPP-4 inhibitors with longer half-lives. Additionally, the gestational diabetes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of gestational diabetes, rising maternal age, and a growing emphasis on maternal and fetal health.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global dipeptide peptidase 4 inhibitors market in 2023 owing to the widespread accessibility and convenience offered by retail outlets, facilitating easy procurement of medications for patients with diabetes. For instance, in October 2023, GSK presented studies at a diabetes conference that suggested better cardiovascular outcomes might result from taking a DPP-4 inhibitor in addition to another diabetic medicine. Additionally, the online channels segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digitalization in healthcare, the convenience of online purchasing, and the expanding e-commerce infrastructure.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of diabetes, increasing awareness about diabetes management, and the early adoption of advanced therapeutic options. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of diabetes, rising awareness about diabetes management, improving healthcare infrastructure, and a growing focus on preventive healthcare measures. For instance, in September 2023, Daiichi Sankyo announced a collaboration with a medical device firm to create a combination treatment that combines Evogliptin with an implanted insulin pump for improved diabetes control.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Diabetes, especially type 2, affects millions of people globally and is a serious global health problem. An increasing number of people need efficient diabetes treatment methods due to the condition's rising incidence, which is fueled by factors including obesity, sedentary lifestyles, and aging populations. DPP-4 inhibitors are a popular choice among patients and medical professionals since they provide a secure and efficient means of regulating blood sugar levels. For instance, Boehringer Ingelheim and Eli Lilly will introduce a novel combination medicine containing metformin and linagliptin in September 2023 to enhance glucose management.
By type, the sitagliptin segment accounted for the highest revenue-grossing segment in the global dipeptide peptidase 4 inhibitors market in 2023 owing to the compound's widespread adoption as a first-line treatment for type 2 diabetes, its established efficacy in glycemic control, and its favorable safety profile. For instance, in August 2023, the FDA approved Novartis's Galvus extended-release pills, which provide the convenience of a once-daily dosage. Additionally, the alogliptin segment is predicted to grow at the fastest CAGR during the forecast period owing to the drug's unique pharmacological characteristics, increasing research and development activities, and a growing recognition of its efficacy in glycemic control.
By application, the type 2 diabetes segment accounted for the highest revenue-grossing segment in the global dipeptide peptidase 4 inhibitors market in 2023 owing to the escalating prevalence of type 2 diabetes worldwide, the increasing adoption of DPP-4 inhibitors as a preferred oral treatment option, and the growing emphasis on personalized and effective management strategies for individuals with type 2 diabetes. For instance, in July 2023, AstraZeneca and Merck & Co. will work together on a research project to create next-generation DPP-4 inhibitors with longer half-lives. Additionally, the gestational diabetes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of gestational diabetes, rising maternal age, and a growing emphasis on maternal and fetal health.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global dipeptide peptidase 4 inhibitors market in 2023 owing to the widespread accessibility and convenience offered by retail outlets, facilitating easy procurement of medications for patients with diabetes. For instance, in October 2023, GSK presented studies at a diabetes conference that suggested better cardiovascular outcomes might result from taking a DPP-4 inhibitor in addition to another diabetic medicine. Additionally, the online channels segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digitalization in healthcare, the convenience of online purchasing, and the expanding e-commerce infrastructure.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of diabetes, increasing awareness about diabetes management, and the early adoption of advanced therapeutic options. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of diabetes, rising awareness about diabetes management, improving healthcare infrastructure, and a growing focus on preventive healthcare measures. For instance, in September 2023, Daiichi Sankyo announced a collaboration with a medical device firm to create a combination treatment that combines Evogliptin with an implanted insulin pump for improved diabetes control.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Application, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Dipeptide Peptidase 4 Inhibitors Market Report 2023 - 2034
Dipeptide Peptidase 4 Inhibitors Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Sitagliptin
- Saxagliptin
- Linagliptin
- Alogliptin
- Vildagliptin
- Others DPP-4 inhibitors
Dipeptide Peptidase 4 Inhibitors Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Type 2 Diabetes
- Gestational Diabetes
- Metabolic Syndrome
- Others
Dipeptide Peptidase 4 Inhibitors Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Dipeptide Peptidase 4 Inhibitors Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Dipeptide Peptidase 4 Inhibitors Market: Type Estimates & Trend Analysis
8. Dipeptide Peptidase 4 Inhibitors Market: Application Estimates & Trend Analysis
9. Dipeptide Peptidase 4 Inhibitors Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Dipeptide Peptidase 4 Inhibitors Market
12. Europe Global Dipeptide Peptidase 4 Inhibitors Market
13. Asia Pacific Global Dipeptide Peptidase 4 Inhibitors Market
14. Latin America Global Dipeptide Peptidase 4 Inhibitors Market
15. MEA Global Dipeptide Peptidase 4 Inhibitors Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Merck & Co. Inc.
- Novartis International AG
- AstraZeneca plc
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Bristol Myers Squibb Company
- Pfizer Inc.
- Sanofi S.A.
- Johnson & Johnson
- GlaxoSmithKline plc
- Daiichi Sankyo Company
- Limited
- Sun Pharmaceutical Industries Ltd.
- Hanmi Pharmaceutical Co. Ltd.
- Jiangsu Hengrui Medicine Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 11.47 Billion |
| Forecasted Market Value ( USD | $ 15.81 Billion |
| Compound Annual Growth Rate | 2.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
